Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

[Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B].

Shi JP, Lu L, Qian JC, Ang J, Xun YH, Guo JC, Shi WL, Wang YF, Fan JG.

Zhonghua Gan Zang Bing Za Zhi. 2012 Apr;20(4):285-8. doi: 10.3760/cma.j.issn.1007-3418.2012.04.012. Chinese.

PMID:
22964150
2.

[Impact of liver steatosis on the curative effect of pegylated interferon-alpha-2a in patients with chronic hepatitis B].

Xu L, Li P, Shi Q, Mi Y.

Zhonghua Gan Zang Bing Za Zhi. 2015 Feb;23(2):99-102. doi: 10.3760/cma.j.issn.1007-3418.2015.02.005. Chinese.

PMID:
25880974
3.

[Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].

Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.

Zhonghua Gan Zang Bing Za Zhi. 2012 Oct;20(10):737-41. doi: 10.3760/cma.j.issn.1007-3418.2012.10.006. Chinese.

PMID:
23207332
4.

[Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].

Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.

Zhonghua Gan Zang Bing Za Zhi. 2013 May;21(5):335-9. doi: 10.3760/cma.j.issn.1007-3418.2013.05.006. Chinese.

PMID:
24025132
5.

[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].

Yue W, Yuan H, Mao XR, Deng YD, Chen L.

Zhonghua Gan Zang Bing Za Zhi. 2013 Mar;21(3):184-8. Chinese.

PMID:
23967738
6.

The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.

Dogan UB, Golge N, Akin MS.

Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1312-6. doi: 10.1097/MEG.0b013e328362389a.

PMID:
23652913
7.

[HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].

Chen XF, Chen XP, Ma XJ, Chen WL, Luo XD, Liao JY.

Zhonghua Gan Zang Bing Za Zhi. 2013 Jul;21(7):502-5. doi: 10.3760/cma.j.issn.1007-3418.2013.07.007. Chinese.

PMID:
24074707
8.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

9.

Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.

Wang YD, Zhao CY, Wang W, Shen C, Lu HZ, Zhang L, Yu WY, Zhou JY, Yan WZ.

Hepatogastroenterology. 2012 May;59(115):680-6. doi: 10.5754/hge12183.

PMID:
22441104
10.

Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection.

Cindoruk M, Karakan T, Unal S.

J Clin Gastroenterol. 2007 May-Jun;41(5):513-7.

PMID:
17450036
11.

Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.

Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.

Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1165-9. doi: 10.1097/MEG.0b013e3283612e95.

PMID:
23571612
12.

Hepatic Steatosis as a Predictive Factor of Antiviral Effect of Pegylated Interferon Therapy in Patients With Hepatitis B.

Gong L, Liu J, Wang J, Lou GQ, Shi JP.

Transplant Proc. 2015 Dec;47(10):2886-91. doi: 10.1016/j.transproceed.2015.10.023.

PMID:
26707308
13.

Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.

Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.

Antivir Ther. 2015;20(2):217-24. doi: 10.3851/IMP2832. Epub 2014 Aug 20.

PMID:
25138110
14.

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L, Mari T, De Santis A, Ponti ML, Sorbello O, Iacomi F, Angelico M.

Antivir Ther. 2009;14(8):1165-74. doi: 10.3851/IMP1466.

PMID:
20032546
15.
16.

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, Choi PC, Chan AW, Sung JJ, Chan HL.

Hepatology. 2010 Jun;51(6):1945-53. doi: 10.1002/hep.23568.

PMID:
20209602
17.

[Liver histopathological features influencing HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B responding to Peg-IFN treatment].

Yan HD, Jiang FR, Zhu CL, Gao GS, Weng PJ, Hu AR, Xu CF, Hu YR, Sheng JF.

Zhonghua Gan Zang Bing Za Zhi. 2013 May;21(5):340-4. doi: 10.3760/cma.j.issn.1007-3418.2013.05.007. Chinese.

PMID:
24025133
18.

Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients.

Zhou P, Yang F, Wang J, Mao R, Qi X, Huang Y, Zhang J.

Medicine (Baltimore). 2015 May;94(17):e730. doi: 10.1097/MD.0000000000000730.

19.

[Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].

Wang M, Zheng W, Zhang H, Li Z, Jiang D, Liu Y, Zhou R, Li XG, Zhang Y, Zhang Z, Wu S, Zhang Y, Li J.

Zhonghua Gan Zang Bing Za Zhi. 2014 Apr;22(4):255-9. doi: 10.3760/cma.j.issn.1007-3418.2014.04.004. Chinese.

PMID:
25173222
20.

An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study.

Chon YE, Kim DJ, Kim SG, Kim IH, Bae SH, Hwang SG, Heo J, Jang JW, Lee BS, Kim HJ, Jun DW, Kim KM, Chung WJ, Choi MS, Jang JY, Yim HJ, Tak WY, Yoon KT, Park JY, Han KH, Suk KT, Lee HW, Jang BK, Ahn SH.

Medicine (Baltimore). 2016 Apr;95(14):e3026. doi: 10.1097/MD.0000000000003026.

Supplemental Content

Support Center